Rosemont Pharmaceuticals will operate as an independent entity following acquisition a by Inflexion private equity. With more than 50 years’ experience and an extensive range of both licensed products and specials within the UK, Rosemont are the experts in liquid medicines with a portfolio of over 130 oral liquid medicines which includes over 70 licensed products.
As a result of the change of ownership Rosemont Pharmaceuticals hope to be able to develop the business to the benefit of their healthcare professional customers through increased investment in innovation and product development, bringing a more extensive range of medicines to the vulnerable patients who need them.
Howard Taylor who has been appointed CEO of Rosemont Pharmaceuticals following the sale commented “We’re extremely pleased to be able to announce this exciting new chapter for Rosemont. As a very well established, and much respected supplier in the industry, we look forward to being able to provide an even wider range of quality products in the future.” Simon Turner, Managing Partner at Inflexion, added: “We are delighted to be partnering with Rosemont on their journey to become an independent business. Our experience in carving businesses out combined with our success in growing healthcare businesses make us confident our partnership will be an excellent foundation for further innovation and new product development.”
